Keeping Track: US FDA Clears On Target’s Cytalux, VBI’s PreHevbrio; Keytruda Grows In Adjuvant Melanoma

The US Food and Drug Administration’s drugs and biologics centers both closed out November with a novel approval – On Target Laboratories LLC’s fluorescent imaging agent Cytalux (pafolacianine) for the Center for Drug Evaluation and Research and VBI Vaccines Inc.’s trivalent hepatitis B vaccine PreHevbrio for the Center for Biologics Evaluation and Research.

The FDA also approved new cancer claims for Merck & Co., Inc